Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 5/20 | 0.44 |
| ▸ | KMO | O15229 | 2/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 9/20 | 0.36 |
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
| ▸ | DRD5 | P21918 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | PTGIR | P43119 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1437062 | 0.88 | CNR1 (0.40) | CHRM1CNR1CNR2DRD1DRD5 | |
| SCHEMBL9894154 | 0.87 | KDM4E (0.39) | MDM2CNR1CNR2 | |
| SCHEMBL9893979 | 0.81 | MDM2 (0.56) | MDM2DRD1DRD5PTGIR | |
| SCHEMBL1437138 | 0.76 | MDM2 (0.51) | MDM2KMODRD1DRD5 | |
| SCHEMBL1438218 | 0.74 | MDM2 (0.71) | MDM2 | |
| SCHEMBL9893683 | 0.73 | MDM2 (0.73) | MDM2DRD1DRD5 | |
| Acetamide SCHEMBL27879129 | 0.73 | MDM2 (0.48) | MDM2KMODRD1DRD5 | |
| SCHEMBL1442682 | 0.71 | MDM2 (0.72) | MDM2KMO | |
| SCHEMBL9893757 | 0.71 | MDM2 (0.62) | MDM2KMO | |
| SCHEMBL1437085 | 0.70 | MDM2 (0.43) | MDM2CNR1CNR2DRD1DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | NOVARTIS AG (CH) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | MDM4, MDM2, TP53 | MDM2 2/4885KMO 857/4885CHRM1 465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.